You have to have a profit on your short. Why don't you just cover and move on to some other #$%$ stock? You're running out of reasons why ETAK sucks
It will take more news driven events/ execution from the company (debt financing/Iucacell migration) to take us above $1.00. Good time to accumulate while the big boys play their games
Better things tend to happen when you don't watch stock prices for 1 year!!! I don't think I gave you a nickname
Many insightful posters have opined on past mis-steps, failures (myself included) of the company and it's management team. How does any mis-step they've done in the past trump Iusacell, HP partnership and Vodaphone expansion and the POTENTIAL this company has!!!!! We're all guessing about an un-certain future and I like my guess about ETAK's future
FEB 2014 Barcelona conference seems to me the coming out party for DNA 2.0. I wonder if Iusacell wanted to wait for this software version for migrations to begin. Could explain the delay that hewey, duey and louie keep whining about. HP a partner and re-seller!! After reading this who wouldn't want to be an INVESTOR in this company???
It is standard operating procedure to include these items in their annual meeting. The one item I noticed was 33% of their awards were based on deal closings
They issued a convertible that can be exercised at any time at a share price of $6.10. That sounds like loan-shark terms to me
Not related to the debt deal currently under consideration to satisfy NYSE. Standard stock/option awards per year in their compensation plan. Rather generous per usual, but standard:
"Our Board of Directors has approved an amendment to the Amended and Restated Elephant Talk Communications Corp. 2008 Long-Term Incentive Compensation Plan, as amended (the “2008 Plan”) to increase the number of shares of common stock available for issuance thereunder by 10,000,000 shares, from 46,000,000 shares to 56,000,000 shares, and directed that the amendment be submitted to the stockholders for approval at the Annual Meeting"
I see the money changers have brought in their expert copy and paster rogerxavier. Here are some comments from the recent "investigative" blog:
August 26, 2014 at 12:54 am
If anyone had simply took the time to address or substantiate what was written here it would’ve been a completely different story. I am the CEO for Dream Team and everything that is written about my company and my investigators couldn’t be farther more the truth. Logic would tell you that no one single investigative site could possibly conduct a 500 patient clinical study. There were 30+ clinical
sites involved and we only accounted for 28 of those randomized. As for the temp excursions, our IP was continually monitored and we had no such fluctuations.
[@David - Agreed that one site makes little sense. That is what made the story so strange, and worthy of investigation. If there were indeed 30+ clinical sites involved, why do the records at Clinicaltrials.gov only show one site, yours? - Editor]
August 26, 2014 at 12:47 am
I am the CEO for Dream Team and everything you wrote regarding my site is false. Next time do your due diligence before posting false information.
[@David - If you could please specify what is incorrect, we would be happy to update. Clearly you can see that Dream Team is indeed the only listed site on Clinicaltrials.gov - Editor]
I like all of your dates except #4. Believe it will be enrolled much quicker. Your posts have been much appreciated over the last few days as well as brother and JT
The $$ per SIMM will always be a moving metric so assuming an average between $.33-$.40 seems like a solid guess. Stock price on a profitable company has historically been about a quantifiable metric such as P/E or multiple of sales. Supply and demand should skew towards the demand side with proper execution (NYSE, Iusacell migration, Vodaphone expansion, HP win justifying sales collaboration). Satisfying NYSE listing requirement 1st and foremost on the list in helping skew the supply/demand equation. Flat-lining stocks (ETAK over the last 2 1/2 months???) sometimes present wonderful opportunities. The theory is they're about to move violently one way or the other. I'm betting with the good guys on this one
Looks like you are coming up with a value for the company based on total SIMMS. Based on 20MM SIMMS generating 80-100MM in revenue you are estimating a $.33-$.40 per SIMM/per month revenue rate. I'm good with that!!! I would also like to throw out a traditional P/E valuation instead of multiple of revenue. Fully diluted share count will take another 2,3,4 years to reach 200MM, but assuming that number currently and assuming full migration of Iusacell + doubling of Vodaphone SIMM count should take this company comfortably above $.10 per year( I believe the number will come in between $.15-$.20 per year because the calculation won't be based off of 200MM shares next year). Why not have a 20 P/E with a company growing over 100% year over year. All of this without 1 PENNY CONTRIBUTION FROM THE BIGGEST DEAL IN THE COMPANY"S HISTORY (HP). Divide by 4 if you want to at look quarterly numbers and my belief is we'll start to see proof of this trajectory in Q4 2014. Q1 2015 should really start to prove the business model
Wonder what the 4 countries are??? From the PR:
"Elephant Talk's ET Software DNA® 2.0 platform is currently providing services to MNOs in four different countries."
Well said. Seems like not enough attention is being paid to this global sales collaboration. Win #1 with that global sales collaboration should change that.